Trial Information
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Inclusion Criteria:
- Adult patients with CTCL that are starting new form of treatment and adult patients
with benign dermatoses.
Exclusion Criteria:
- patients with lymphomas other than CTCL or leukemia
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Measure the levels of Th 17 cytokines namely Il-17 and Il-22 in CTCL
Outcome Time Frame:
2 -3 years
Safety Issue:
No
Principal Investigator
Sergei Koralov, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
NYU School of Medicine
Authority:
United States: Institutional Review Board
Study ID:
11-01293
NCT ID:
NCT01663571
Start Date:
May 2012
Completion Date:
Related Keywords:
- Cutaneous T Cell Lymphoma
- Inflammation
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
Name | Location |
NYU Langone Medical Center |
New York, New York 10016 |